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INTRODUCTION
Colorectal cancer arises from a series of somatically inher-
ited changes, including mutations and transmissible epige-
netic events such as methylation of CpG islands (1), some or
all of which produce a growth advantage relative to surround-
ing cells (2, 3). Among the epigenetic events involved in
tumorigenesis are DNA methylation, genomic imprinting,
and histone modification (4). Global decreases in 5-methyl-
cytosine content have been associated with tumor forma-
tion, including that of colorectal cancers. Another molecu-
lar defect commonly occurring during neoplasia is de novo
CpG island methylation (4-6). Recently, a distinct pathway
of colorectal carcinogenesis was described, termed the CpG
island methylation phenotype (CIMP) (7). This pathway
was uncovered through a series of observations that includ-
ed association between microsatellite instability (MSI) and
hypermethylation of multiple genes, from the concordance
between the methylation status of different genes unrelated
to the gene function or chromosomal location, and from the
bimodal distribution of methylation in a selected subset of
genes.
Colorectal cancer is the third leading cause of cancer-relat-
ed deaths worldwide (8). Almost 70% of all colorectal can-
cers are sporadic. Of the remaining 30%, a small number
belong to the familial syndromes of hereditary nonpolyposis
colorectal cancer (HNPCC) and familial adenomatous poly-
posis (FAP), whereas the vast majority show non-syndromat-
ic familial susceptibility (9). The proportion of all cases con-
sidered familial depends in the definition. Of all patients with
colorectal cancer, 11-16% have at least one first-degree rela-
tive with colorectal cancer (10, 11), but the proportion is
much higher if second- or third-degree relatives are consid-
ered. In one study, 53% of colorectal cancer probands had a
first-degree relative with cancer (11). In fact, first-degree rel-
atives of patients affected by colorectal cancer, but who do not
fulfill the criteria for FAP and HNPCC, have a more than
2-fold increased risk of developing tumors of the large intes-
tine (12). 
HNPCC is caused by germline mutations in the mismatch
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CpG Island Methylation in Familial Colorectal Cancer Patients Not
Fulfilling the Amsterdam Criteria
To determine the role of methylation in colorectal cancer patients with a family his-
tory, we enrolled 25 colorectal cancer patients with a family history of colorectal
cancer but without a mutation in the hMLH1 and hMSH2 genes. Thirty patients
with sporadic colorectal cancer were included as control. The methylation status of
COX2, MGMT, hMLH1, TIMP3, p16, and MINT2 in normal mucosa and tumor
were assessed using methylation-specific PCR. In patients with a family history,
the methylation frequency ranged from 4.0% for TIMP3 to 44.4% for MGMT, where-
as, in patients with sporadic colorectal cancer, it ranged from 6.7% for TIMP3 to
50.0% for p16. Nine of the 25 patients with family history (36.0%) were classified
as methylation-prone, and nine of the 30 patients with sporadic cancers (30.0%)
were as methylation-prone, making their methylation indices 0.19 and 0.16, respec-
tively (p=0.522). As for the individual genes, the methylation rate of MGMT was
higher in colorectal cancer patients with family history (44.0% vs. 13.0%, p=0.016),
whereas the methylation rate of p16 was higher in sporadic colorectal cancers (50.0%
vs. 8.7%, p=0.046). While CpG island methylation of tumor suppressor genes may
play a role in colorectal carcinogenesis, the genes involved may be different between
tumors of patients with and without a family history of colorectal cancer.
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repair (MMR) genes hMLH1,hMSH2,hMSH6, and hPMS2,
with a penetrance of approximately 80% for colorectal can-
cer, 60% for endometrial cancer, and below 20% for other
cancers (13). HNPCC is characterized by early onset, the
development of neoplastic lesions in a variety of tissues, and
MSI. The Amsterdam criteria for HNPCC are strictly defined
and exclude most tumors suspected of being hereditary. In
contrast, the Bethesda guidelines broaden the disease spec-
trum by including colorectal cancer families with specific
accompanying cancers and clinicopathologic characteristics
(13, 14). These latter criteria provide important clues for
identifying genetic pathways associated with atypical phe-
notypes of hereditary colorectal cancer. Although the strict
Amsterdam criteria could be used to detect underlying molec-
ular events in hereditary colorectal cancers, only 50% (range,
30-80%) of cases involve a detectable germline mutation in
an MMR gene (15). Therefore, by restricting the definition
of HNPCC to tumors containing an MMR germline muta-
tion, only about 2.5% of colorectal cancers are thought to
be caused by HNPCC. Thus, the carcinogenesis pathways
and molecular events in familial cancers with no detectable
germline mutations and/or not fulfilling HNPCC criteria,
remain to be determined. 
In this study, familial colorectal cancer was defined broad-
ly to include colorectal cancer patients who have at least one
first-degree relative with colorectal cancer. Although these
cancers may have a familial tendency clinically, their heredi-
ty has not been determined yet. Molecular profiles, includ-
ing promoter methylation, have not been thoroughly exam-
ined in these types of tumors. To broaden our understanding
of carcinogenesis in these colorectal cancers, and to deter-
mine the effect of methylation in familial colon tumors not
fulfilling the Amsterdam criteria, we assayed the methyla-
tion status of the promoter region of several tumor-related
genes. 
MATERIALS AND METHODS
Characteristics of patients and specimens
We enrolled 25 colorectal cancer patients with a family
history of colorectal cancer, defined as at least one first-degree
relative with colorectal cancer, but who did not meet the
strict Amsterdam criteria I and II for HNPCC. None of these
patients was known to have germline mutations in hMLH1
and hMSH2, indicative of HNPCC in the previous study
(16). Family history was obtained from answers to a ques-
tionnaire and from an interview with a physician at the col-
orectal cancer clinic of Asan Medical Center. Patients with a
vague family history and those with polyposis were exclud-
ed. As a control group, we enrolled 30 patients with spo-
radic colorectal cancers and no family history of colon tumors,
including adenomas and HNPCC-related tumors in first-
and second-degree relatives. This study was approved by the
institutional review board of the hospital, and written inform-
ed consent was obtained from all the participants prior to the
study entry. 
The colorectal cancers with family history tended to be
located in colon rather than in rectum, and there was no dif-
ference in other clinicopathologic variables between two
groups (Table 1). All 55 tumors were confirmed as adeno-
carcinomas upon histologic examination. After resection,
tumor and non-neoplastic colonic mucosa (mucosa) were
obtained and stored at -80℃until DNA extraction. 
Sodium bisulphite modification and methylation-specific
PCR (MSP)
MSP distinguishes unmethylated from methylated alleles
based on sequence alterations produced by treatment of DNA
with bisulphite, which converts unmethylated, but not methy-
lated, cytosine to uracil, followed by polymerase chain reac-
tion (PCR) using primers specific to methylated or unmethy-
lated DNA (17). The methylation status of 6 genes was anal-
ysed by MSP: COX2, MGMT, hMLH1, TIMP3, p16, and
MINT2. One microgram of genomic DNA was denatured
Variables Familial CRC  Sporadic CRC p value
Sex
Male 15 16 0.62
Female 10 14
Age (yr)
≤60 13 14 0.69
>60 12 16
Location
Colon 16 8 0.007
Rectum 9 22
Size (cm)
≤5 10 21 0.03
>5 15 9
T
1 1 1 0.85
25 8
31 9 2 1
N
0 18 15 0.17
1-2 7 15
Serum CEA (ng/mL) 
≤6 16 22 0.46
>6 9 8
Differentiation
WD, MD 22 28 0.51
PD, MUC 3 2
Total 25 30
Table 1. Clinicopathologic features of patients with a family his-
tory of colorectal cancers and those with sporadic colorectal
cancers
CRC, colorectal cancer; CEA, carcinoembryonic antigen; WD, well-dif-
ferentiated; MD, moderately differentiated; PD, poorly differentiated;
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with NaOH and modified with sodium bisulphite. The DNA
samples were purified using Wizard DNA purification resin
(Promega, Madison, WI, U.S.A.) and resuspended in ddH2O.
PCR was performed using a mixture containing 10×PCR
buffer (16.6 mM ammonium sulphate, 67 mM Tris (pH
8.8), 6.7 mM MgCl2, and 10 mM 2-mercaptoethanol), 1.25
mM of each dNTP, 300 ng of each primer, and bisulphite-
modified DNA (50 ng) in a final volume of 50  L. Follow-
ing a hot start at 95℃ for 5 min, 1.25 units of Taq poly-
merase (Promega) were added, and amplification was carried
out in a Hybaid OmniGene temperature cycler (Hybaid,
Middlesex, United Kingdom) using previously reported
primer sequences and PCR conditions (18). Control PCR
reactions lacking genomic DNA were performed for each
set of reactions. Ten microliters of each PCR reaction prod-
uct were electrophoresed on nondenaturing 6% polyacry-
lamide gels, which were stained with ethidium bromide
and visualized under UV illumination (Fig. 1). Bisulphite
genomic sequencing of representative MSP samples for each
gene was performed, validating the adequacy of the bisulphite
modification and indicating that all of the cytosines at non-
CpG sites were converted to thymines. All of the sequenced
MSP products showed extensive methylation of CpG sites
within the primer sequences.
Grouping of adenomas and carcinomas by promoter
methylation status
Tumors were classified as methylation-resistant (MR) if
fewer than two loci were methylated or methylation-prone
(MP) if two or more loci were methylated. Each tumor and
group were represented by a methylation index (number of
loci methylated/number of loci evaluated).
MSI
MSI status was determined by PCR using primers to am-
plify the five microsatellite markers recommended by the
National Cancer Institute (Bethesda, MD., U.S.A.), i.e.,
BAT25, BAT26, D17S250, D5S346, and D2S123 (13).
Denaturation of the PCR products, gel electrophoresis, and
silver staining were performed as described. MSI was scored
as positive when there was a definite shift of PCR product
in tumor DNA compared with normal mucosal DNA. All
MSI-positive loci were confirmed on duplicate examinations.
Tumors with MSI in at least two loci were classified as high-
frequency MSI (MSI-H), tumors with MSI at one locus were
classified as low frequency MSI (MSI-L), and tumors with
MSI at no locus were classified as microsatellite stable (MSS).
Statistical analysis
The interactions between methylation and clinicopatholog-
ic parameters in two groups were evaluated with chi-square
tests and Fisher’s exact tests. All p values were two-sided, and
a p value less than 0.05 was considered statistically signifi-
cant. Calculations were performed using the SPSS program
(Version 12.0, Chicago, IL, U.S.A.).
RESULTS 
Methylation in colorectal cancer patients with family history
We determined CpG island methylation at six loci and MSI
in paired normal mucosa and tumor tissue from 25 colorec-
tal cancer patients with family history. Of the 25 tumors,
16 (64.0%) showed promoter methylation of at least one
gene, ranging to four genes. Seven tumors showed methyla-
tion at one gene, seven at two genes, one at three genes, and
one at four genes. In contrast, of the 25 samples of normal
colonic mucosa, 12 (48.0%) showed promoter methylation:
eight samples at one gene, and four samples at two genes.
When patients with a family history were categorized as hav-
ing 0-1 (MR group) or ≥2 (MP group) methylated loci, we
found that 36.0% of the tumors and 16.0% of the normal
mucosa samples could be categorized as MP. The mean methy-
lation index (the number of methylated loci divided by the
total number of tested loci) was 0.11 (0-0.33) in normal
mucosa and 0.19 (0-0.66) in tumors (p=0.078). A high pro-
portion of tumors (44.0%) were methylated at the MGMT
locus, whereas 20.0%, 20.0%, and 16.0% were methylated
at the COX2, hMLH1, and MINT2 loci, respectively. In con-
trast, only 8.0% of p16 loci and 4.0% of TIMP3 loci were
methylated (Fig. 2). We found that the COX2, MGMT, and
p16 loci were methylated at 28.0%, 20.0%, and 16.0%,
respectively, of normal mucosa samples of patients with a
family history, whereas the hMLH1, TIMP3, and MINT2
loci were not methylated in any of the normal mucosa sam-
ples. The frequency of methylation of the COX2 and p16 loci
was higher in normal mucosa than in tumor, but the differ-
Fig. 1. Methylation status of COX2, MGMT, hMLH1, TIMP3, p16,
and MINT2 using methylation-specific polymerase chain reaction
(MSP) in sporadic colorectal cancers. The samples examined are
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ence did not reach a statistical significance.
Methylation in sporadic colorectal cancer patients
We also assayed CpG island methylation at these six loci
and MSI in paired tumors and normal mucosa from 30
patients with sporadic colorectal cancer. We found that 16
(53.0%) of the tumors showed promoter methylation of at
least one gene, ranging to three genes. Seven tumors show-
ed methylation at one locus, six at two loci, and one at three
loci. In contrast, only 7 (23.0%) of the normal colonic mucosa
samples showed promoter methylation, each at one gene.
We found that 30.0% of the tumors, and none of the nor-
mal mucosa, could be classified as MP. The mean methyla-
tion index was 0.04 (0-0.17) in normal mucosa and 0.16 (0-
0.5) in tumors (p<0.001). Methylation of the p16 locus was
observed in a high proportion (33.3%) of sporadic tumors
cases, whereas methylation of the COX2, MGMT, and MINT2
loci were observed in 20.0%, 13.3%, and 13.3%, respective-
ly, of these tumors. In contrast, only 6.7% of tumors were
methylated at the TIMP3 promoter (Fig. 3). Methylation of
the p16, COX2, and MGMT loci were observed in 13.3%,
6.7%, and 3.4%, respectively, of the normal mucosa sam-
ples, whereas we did not observe methylation of the hMLH1,
TIMP3, and MINT2 loci in any of these tissues.
Correlation of clinicopathologic characteristics and MSP
results
To clarify the clinical significance of the methylation sta-
tus of individual genes or the extent of methylation of mul-
tiple CpG islands, we compared molecular and clinicopatho-
logic features of colorectal cancer patients (Table 2). We did
not detect any differences in clinicopathologic features between
the MP and MR groups or between groups of patients with
or without a family history of colorectal cancer. In the group
of sporadic colorectal cancers, however, we found that the
methylation index was higher in older patients (p<0.001)
and in those with right colon tumors (p=0.041).
Fig. 3. Methylation status of COX2, MGMT, hMLH1, TIMP3, p16,
and MINT2 in normal mucosa and tumor tissue of patients with
sporadic colorectal cancer. In tumors, the locus most frequently

























Variables MR MP p value
Sex
Male 21 8 0.58
Female 16 10
Age (yr)
≤60 21 6 0.15
>60 16 12
Location
Colon 17 7 0.77
Rectum 20 11
Size (cm)
≤5 21 10 0.58
>5 10 8
T
1 1 1 0.29
21 1 2
32 5 1 5
N
0 25 8 0.14
1-2 12 10
Serum CEA (ng/mL) 
≤6 27 11 0.54
>6 10 7
Differentiation
WD, MD 34 16 1.00
PD, MUC 3 2
Group
Familial 16 9 0.74
Sporadic 21 9
MSI
MSI-H 4 2 1.00
MSI-L, MSS 33 16
Total 37 18
Table 2. Clinicopathologic features of patients according to
methyation status
MR, methylation-resistant; MP, methylation-prone colorectal cancer;
CEA, carcinoembryonic antigen; WD, well-differentiated; MD, moder-
ately differentiated; PD, poorly differentiated; MUC, mucinous; MSI-H,
microsatellite instability high frequency; MSI-L, microsatellite instability
low frequency; MSS, microsatellite stable.
Fig. 2. Methylation status of COX2, MGMT, hMLH1, TIMP3, p16,
and MINT2 in normal mucosa and tumor tissues of patients with
a family history of colorectal cancer. In tumors, the locus most
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Comparisons of methylation in patients with and without
a family history of colorectal cancer
The overall frequency of methylation in tumors did not
differ between patients with and without a family history
of colorectal cancer (p=0.524 for methylation index; p=0.774
for MP vs. MR). When we analysed methylation of individ-
ual genes, however, we found that MGMT was more fre-
quently methylated in colorectal cancers of patients with a
family history (p=0.016), whereas p16 was more frequently
methylated in sporadic colorectal cancers (p=0.046) (Fig. 4).
We found that the normal mucosa in patients with family
history showed more frequent methylation than did normal
mucosa of sporadic cancer patients (p=0.016 for methyla-
tion index; p=0.037 for MP vs. MR), but there was no dif-
ference in methylation of any of the individual genes.
MSI
Of the 25 colorectal cancers with family history, four (16.0
%) were MSI-H and five (20.0%) were MSI-L. In contrast,
of the 30 colorectal cancer without family history, two (6.7
%) were MSI-H and 28 (93.3%) were MSS (MSI-H vs. MSI-
L vs. MSS, p=0.014). When we divided the microsatellite
status into two groups (MSI-H vs. MSI-L plus MSS), we
observed no difference between colorectal cancers with and
without family history. We found that the hMLH1 gene was
methylated in three of the MSI-H tumors (50.0%), three of
the MSI-L tumors (60.0%), and one of the MSS tumors
(2.3%). When we analysed the correlations between MSI
and clinicopathologic characteristics, we found that  the
tumors with MSI showed right side predominance (MSI-H
vs. MSI-L plus MSS; p=0.022) and were more frequently
methylated at hMLH1 (p=0.022) and TIMP3 (p=0.029). 
DISCUSSION 
Aberrant methylation in promoter CpG islands of tumor
suppressor genes is associated with transcriptional silencing
of these genes and is thought to be an alternative mechanism
in carcinogenesis (5, 6). Colorectal cancers with CpG island
methylation are thought to have a distinct clinicopathologic
phenotype and genetic profiles, including MSI and frequent
mutations of the K-ras gene, but they lack p53 mutations
(19, 20). There is as yet no consensus about the definition of
CIMP and the panel of CpG sites that should be analysed to
classify tumors as CIMP. This is not trivial, given that each
study uses different methods to assay DNA methylation,
assays different genes, has different definitions of CIMP, and
examines a different minimal number of genes. Genes related
to carcinogenesis may be tissue-dependent, and the defini-
tion of CIMP for colorectal cancer might not be applicable
to other cancers. CIMP has been generally defined as methyla-
tion of at least two MINTs or target genes such as p16, p14,
or hMLH1, when a small panel of such markers is examined
(7, 21, 22).
In the present study, we have assayed six markers: MINT2,
p16, TIMP3, hMLH1, MGMT, and COX2. All of these have
been found to be methylated mainly in cancers and are fre-
quently methylated in gastrointestinal tumors (23, 24). More-
over, these genes have been reported to be closely related to
colorectal carcinogenesis; specifically, cell-cycle regulation
(COX2 and p16), DNA repair or protection (MGMT, and
hMLH1), and metastasis and invasion (TIMP3). In our opin-
ion, this selection satisfies the minimum conditions for study-
ing methylation in colorectal cancer (19). We categorized
colorectal tumors as MP or MR to avoid confusion with other
definitions of CIMP (7, 20, 25), and calculated and compared
methylation indices to reduce the bias from our selection of
genes. 
In this study, we have focused on a subgroup of familial
colorectal cancers; i.e., tumors from patients with first-degree
relatives with colorectal cancers and no germline mutations
in hMLH1 and hMSH2 (16). This group of cancers may be
a mixture of heterogeneous tumors with different molecular
profiles. Several mechanisms of genetic predisposition to col-
orectal cancer with a familial tendency have been suggested.
These include defects in MMR genes other than hMLH1
and hMSH2, low penetrance of polymorphisms, simple phe-
nocopy, or technically undetectable alterations in hMLH1
and hMSH2 (16, 26, 27). Therefore, in interpreting the results
of this study, our definition of familial cancers should be con-
sidered. That is, we enrolled and classified patients as having
familial colorectal cancer, who have been known not to have
a mutation in hMLH1 and hMSH2, and have at least one
first-degree relative without considering familial history of
cancers in other organs and in second-degree relatives. There-
fore, our results may not be representative of the methyla-
tion status in hereditary cancers not fulfilling the Amster-
(%)
Fig. 4. Differences in methylation status of MGMT and p16 in tumors
of patients with a family history of colorectal cancer and in those
with sporadic colorectal cancer. Compared with sporadic colorec-
tal cancers, MGMT was more frequently (p=0.016) and p16 was
less frequently (p=0.046) methylated in colorectal cancers from
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dam criteria of HNPCC. The present study was also limited
by the small number of samples studied.
Several reports have described an association between the
methylation status of multiple genes and a familial tenden-
cy to colorectal cancer (15, 28). A recent large study, how-
ever, found no evidence that patients with heavily methylat-
ed colorectal cancers were more likely to develop a second
malignancy or have a positive family history of cancer (29).
Aberrant methylation may result from an inherited defect
in the methylation apparatus. In this study, considerable pro-
portions of cancer in both groups with or without familial
history of colorectal cancer presented the methylated genes
that may involved in carcinogenetic pathways. It still remains
to be elucidated whether promoter methylation in multiple
genes is one of main mechanism to evoke cancer or simple
bystander. However, our results confirm that CpG island pro-
moter methylation may be a universal event in sporadic or
familial colorectal cancer, and is suggested as one of the mech-
anisms for ‘second hits’ by which tumor suppressor genes
are inactivated. Evidence for this mechanism in familial col-
orectal cancers was previously reported in studies showing
aberrant methylation of individual genes, including CDH1,
VHL, and hMLH1, in hereditary cancer syndromes (30-32). 
Cancer is a genetic disease. Most cancer-causing mutations
are somatic, occurring in the affected tissue during the course
of carcinogenesis. However, most cancers also have a heredi-
tary component, caused by predisposing mutations that affect
the germline, are heritable, contribute to the initiation of
carcinogenesis, and influence the carcinogenesis pathway.
Although hypermethylation is not a rare event, either in
sporadic colorectal cancers or in colorectal cancers with fam-
ily history, predisposing germline alterations can affect detail-
ed aspects of methylation. Our data showed two of the genes
methylated at their promoters, p16 and MGMT, differ accord-
ing to the tumor type. These findings suggest that the methy-
lation of p16, leading to its loss of function, may be a domi-
nant and necessary event for sporadic colorectal carcinogen-
esis, whereas methylation of MGMT may be dominant and
necessary in colorectal carcinogenesis in individuals with a
family history. It was reported that the frequency and pattern
of gene methylation varied between HNPCC syndrome and
sporadic adenomas, implying differences in the molecular
pathogenesis of tumors (33). MGMT has been considered as
a critical step of genetic instability and methylation of MGMT
are proposed to show a distinctive phenotype of MSI-L or
mild family history of colorectal cancer (34, 35). The pre-
sent study also showed a possibility that different pathways
to cancer may exit according to the molecular background
and some subgroup of familial colorectal cancer are related
to the loss of function of MGMT. Thus, genes selected for
methylation-induced functional loss may differ according to
the genetic background. While methylation seems to be a
universal mechanism by which gene function is inactivated,
the germline mutations in familial tumors confer a selective
advantage for their tumorigenic growth, but other genetic
and epigenetic lesions are also necessary. Genetic predisposi-
tion to CpG island methylation may be a modifying factor
that contributes to the penetrance of HNPCC. Our findings
thus expand these early observations on methylation in famil-
ial colorectal cancer and highlight the selective advantage of
epigenetic gene silencing. 
A ‘field defect’ is an area of abnormal tissue that predispos-
es to the development of cancer. The molecular basis is rela-
tively simple to understand when it occurs in patients who
have a genetic predisposition for cancer development or mas-
sive exposure to a carcinogen. Within this defective field, a
second change may confer a growth advantage on a given
cell relative to other cells. In colorectal cancer patients with
germline genetic defects, all cells in the colonic mucosa have
the same genetic alteration, leading to the frequent develop-
ment of tumors in these individuals. In some of these pati-
ents, however, the selective advantage of genetic alterations
is not great (36). Methylation has been proposed as a candi-
date mediator of this field defect and methylation status of
normal mucosa was explored to verify the role of methyla-
tion as an earliest event in carcinogenetic pathway (37, 38).
A recent study reported that some colorectal cancers arise
from a field defect defined by epigenetic inactivation of some
genes such as MGMT (38). Detection of this abnormality
may useful in predict the colorectal cancer risk. Germline
defects that alter methylation machinery may increase methy-
lation frequency in normal colonic mucosa of individuals
with a family history of colorectal cancer, and this may be
associated with the frequent and multiple incidences of col-
orectal tumors in these patients. We found that methylation
status of mucosa differed between in the patients of sporadic
and familial colorectal cancers, although we did not detect
differences in individual genes. This finding might be a small
clue that field defect related to methylation has variable effects
regarding selective power and involved genes for field defect
is also diverse according to the specific carcinogenetic path-
way. A methylation field effect in the entire whole colonic
mucosa may be associated with the process of carcinogenesis
in familial colorectal cancer, at least in those tumors with
high methylation rates in normal mucosa. 
Conclusively, alterations in the methylation machinery
may also be associated with both sporadic and familial col-
orectal carcinogenesis, although there are qualitative and
quantitative differences in methylation between sporadic
and familial tumors. Our findings, however, do not support
the concept that a germline defect in the methylation machin-
ery is responsible for the development of most tumors with
multiple epimutation. This epigenetic mechanism can silence
different genes affected by other genetic backgrounds, lead-
ing to divergent pathways of development in hereditary and
sporadic colorectal cancers. 276 H.C. Kim, H.J. Lee, S.A. Roh, et al.
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